Johnson & Johnson

2006 Investor Fact Sheet

Description

- World's most comprehensive and broadly based manufacturer of health care products
- Serves the Consumer, Pharmaceutical and Medical Devices and Diagnostics markets with a focus on research-based, technology-driven products

Consistent Performance

- 74 consecutive years of sales increases
- 23 consecutive years of earnings increases adjusted for special charges
- 45 consecutive years of dividend increases (includes April 2007 dividend increase)
- Annual compounded growth achievements:

	One Year	Five Years	Ten Years
Sales	5.6%	10.5%	9.6%
Diluted Earnings per Share[1]	11.3%	16.3%	14.4%
Dividend Growth	14.1%	15.8%	14.7%
Total Return to Shareholders	12.3%	4.2%	12.0%

[1]*As reported, GAAP*

Broadly Based/Exceptional Financial Strength

- Over 250 operating companies in 57 countries selling products throughout the world (44% of sales outside of U.S.)
- Sales split among Consumer, Pharmaceutical and Medical Devices and Diagnostics business segments
- More than 100 drugs marketed; 32 drugs over $50 million; 23 drugs over $100 million; 8 drugs over $1 billion
- One of a few U.S. industrial companies that still commands a Triple A credit rating by both Standard & Poor's and Moody's credit rating agencies
- Generated approximately $11.6 billion annual free cash flow in 2006





Worldwide Market Leadership

- Largest Medical Device company
- 5th largest Pharmaceutical company globally
- Leadership Positions in Major Markets:
  - Antipsychotics
  - Baby and Kids Care
  - Blood Glucose Monitoring
  - Coronary Stents
  - Disposable Contact Lenses
  - Hormonal Contraceptives
  - Lo-Cal Sweeteners
  - Minimally Invasive Surgery
  - Orthopaedics
  - Over-the-Counter Pharmaceuticals
  - Sutures
  - Wound Care
- Approximately 70% of sales derived from products/businesses that have a #1 or #2 global market share position

Please visit our Home Page on the Internet at http://www.jnj.com for requests for ***Company Reports,*** including the 2006 Annual Report and SEC filings. Questions regarding stock holdings and the ***Dividend Reinvestment Plan,*** should be directed to: Computershare Trust Company, N.A. Phone (800) 328-9033



This chart provides a comparison of total shareholder return for an investment in Johnson & Johnson Common Stock as of December 31, 2001 to a similar investment in the Standard & Poors 500 Stock Index and the S&P Pharmaceutical Index and the S&P Health Care Equipment Index. Assuming dividends were reinvested, a $100.00 investment in Johnson & Johnson would have grown to $122.54 as of December 31, 2006. This compares to a value of $134.46 for the S&P 500 Stock Index and $90.05 for the S&P Pharmaceutical Index and $140.69 for the S&P Health Care Equipment Index.
Source: Bloomberg.







Strong Commitment to New Product Development

- $7.1 billion in Research & Development spending in 2006
- Approximately 100+ external alliances and collaborations entered into annually
- Approximately 30% of products sold in 2006 introduced in last 5 years

Well Positioned for Future Growth

- Solid pipeline of new and innovative products
- U.S. demographics point to high growth in health care industry
- Broad geographic reach provides ability to rapidly introduce new products in markets around the world
- Focus on products which reduce the cost of health care
- Management based on a core set of Strategic Principles: Broadly based in human healthcare, decentralized management structure, long term focus and Credo based decision making.

Investor Information

***NYSE Symbol:* JNJ**

For additional information, contact:
Investor Relations Department
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
Voice: (800) 950-5089
Fax: (732) 524-3867

Press releases, including earnings reports, are available via web access:
http://www.jnj.com

© Johnson & Johnson 2007